Is 5-ALA fluorescence of cerebral metastases a prognostic factor for local recurrence and overall survival?
- PMID: 30535595
- DOI: 10.1007/s11060-018-03066-y
Is 5-ALA fluorescence of cerebral metastases a prognostic factor for local recurrence and overall survival?
Abstract
Background: 5-Aminolevulinic acid (5-ALA) fluorescence-guided resection technique was first introduced for malignant glioma. However, the impact of the 5-ALA fluorescence behaviour of cerebral metastases is still unclear. Aim of this study was to determine the impact of PpIX-fluorescence on the local progression-free and overall survival.
Materials and methods: A secondary analysis was performed and included an updated follow-up of 136 patients comprised in two previous studies. Additionally, 82 new patients were included. All patients underwent surgical resection of cerebral metastasis and intraoperative estimation of 5-ALA-induced fluorescence. The 5-ALA fluorescence behaviour of cerebral metastases was correlated with the rate of local recurrences, the local progression-free and overall survival.
Results: 218 patients suffering from cerebral metastatic spread fulfilled the inclusion criteria and were analysed: complete surgical resection could be achieved in 123/218 patients (56.4%). Dichotomised degree of surgical resection (complete vs. incomplete or questionable complete resection) was not related to dichotomized 5-ALA fluorescence of cerebral metastases (p = 0.66). 51 patients (23.4%) developed a local in-brain progression within or at the border of the resection cavity. Of these, 8 patients showed a PpIX-fluorescent metastasis. There was a trend towards a correlation between a higher local in-brain progression in PpIX-non-fluorescent metastases (p = 0.03). Median time to local in-brain progression was 4 ± 11 months. PpIX-fluorescent and PpIX-non-fluorescent metastases showed a significantly different progression-free survival (p = 0.01). PpIX-positive and -negative metastases showed a significantly different overall survival (20 and 14 months respectively; p = 0.006).
Conclusion: The 5-ALA fluorescence behaviour was related to the local progression-free and the overall survival in the present retrospective series and might be considered a prognostic marker. Further studies are required to appreciate the oncological impact of the 5-ALA induced fluorescence behaviour of cerebral metastases.
Keywords: 5-Aminolevulinic acid; Cerebral metastases; In-brain-progression; Overall survival; Recurrence.
Similar articles
-
5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression.Oncotarget. 2016 Oct 11;7(41):66776-66789. doi: 10.18632/oncotarget.11488. Oncotarget. 2016. PMID: 27564260 Free PMC article.
-
Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.Clin Exp Metastasis. 2019 Oct;36(5):467-475. doi: 10.1007/s10585-019-09986-x. Epub 2019 Aug 2. Clin Exp Metastasis. 2019. PMID: 31376098
-
Analysis of 5-aminolevulinic acid-induced fluorescence in 55 different spinal tumors.Neurosurg Focus. 2014 Feb;36(2):E11. doi: 10.3171/2013.12.FOCUS13485. Neurosurg Focus. 2014. PMID: 24484249
-
The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience.J Neurooncol. 2019 Feb;141(3):507-515. doi: 10.1007/s11060-018-03061-3. Epub 2018 Dec 1. J Neurooncol. 2019. PMID: 30506501
-
The role of 5-aminolevulinic acid in spinal tumor surgery: a review.J Neurooncol. 2019 Feb;141(3):575-584. doi: 10.1007/s11060-018-03080-0. Epub 2018 Dec 29. J Neurooncol. 2019. PMID: 30594965 Free PMC article. Review.
Cited by
-
Does 5-ALA Fluorescence Microscopy Improve Complete Resectability in Cerebral/Cerebellar Metastatic Surgery? A Retrospective Data Analysis from a Cranial Center.Cancers (Basel). 2024 Jun 17;16(12):2242. doi: 10.3390/cancers16122242. Cancers (Basel). 2024. PMID: 38927947 Free PMC article.
-
Established and emerging uses of 5-ALA in the brain: an overview.J Neurooncol. 2019 Feb;141(3):487-494. doi: 10.1007/s11060-018-03087-7. Epub 2019 Jan 3. J Neurooncol. 2019. PMID: 30607705 Review.
-
Surgical advances in the management of brain metastases.Neurooncol Adv. 2021 Nov 27;3(Suppl 5):v4-v15. doi: 10.1093/noajnl/vdab130. eCollection 2021 Nov. Neurooncol Adv. 2021. PMID: 34859228 Free PMC article.
-
Epidemiology and palliative care of in-patient cerebral metastases cases in Germany.J Neurooncol. 2025 May;173(1):37-48. doi: 10.1007/s11060-024-04928-4. Epub 2025 Apr 11. J Neurooncol. 2025. PMID: 40214907 Free PMC article.
-
Experience Profiling of Fluorescence-Guided Surgery II: Non-Glioma Pathologies.Brain Tumor Res Treat. 2019 Oct;7(2):105-111. doi: 10.14791/btrt.2019.7.e39. Brain Tumor Res Treat. 2019. PMID: 31686441 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical